Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.
暂无分享,去创建一个
Tatiana Nikolskaya | Yuri Nikolsky | Eugene Kirillov | Yan A Ivanenkov | Nikolay P Savchuk | Konstantin V Balakin | T. Nikolskaya | Y. Nikolsky | E. Kirillov | K. Balakin | N. Savchuk | Y. Ivanenkov | A. Ivashchenko | Dmitry Korolev | Dmitry Korolev | Andrey A Ivashchenko
[1] Konstantin V. Balakin,et al. Property-Based Design of GPCR-Targeted Library , 2002, J. Chem. Inf. Comput. Sci..
[2] M. Kietzmann. Conjugation Reactions in Drug Metabolism: Mulder, G.J. (Ed.), X+413 pp., London, New York, Philadelphia: Taylor and Francis (1990) , 1991 .
[3] P. Shields,et al. Cytochrome P4502E1 (CYP2E1) genetic polymorphism in a case-control study of gastric cancer and liver disease. , 1995, Pharmacogenetics.
[4] S. Ekins,et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.
[5] F. Gonzalez,et al. Human cytochromes P450: evolution and cDNA-directed expression. , 1992, Environmental health perspectives.
[6] L. Koymans,et al. Cytochromes P450: their active-site structure and mechanism of oxidation. , 1993, Drug metabolism reviews.
[7] R. Obach,et al. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[8] N Bodor. Retrometabolic approaches for drug design and targeting. , 1997, Die Pharmazie.
[9] R. Cattell,et al. A Comprehensive Trial Of The Scree And Kg Criteria For Determining The Number Of Factors. , 1977, Multivariate behavioral research.
[10] L. Hederstedt,et al. Molecular biology of cytochromes , 1992 .
[11] I. Jolliffe. Principal Component Analysis , 2002 .
[12] Sergei V. Trepalin,et al. SLIPPER-2001 - Software for Predicting Molecular Properties on the Basis of Physicochemical Descriptors and Structural Similarity , 2002, J. Chem. Inf. Comput. Sci..
[13] D. Nebert. Multiple forms of inducible drug-metabolizing enzymes: A reasonable mechanism by which any organism can cope with adversity , 1979, Molecular and Cellular Biochemistry.
[14] Jens Sadowski,et al. The Use of Self-organizing Neural Networks in Drug Design , 2002 .
[15] N. Vermeulen,et al. A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.
[16] F. Darvas,et al. Predicting metabolic pathways by logic programming , 1988 .
[17] R. Remmel,et al. Drug Metabolism Databases and High-Throughput Testing During Drug Design and Development. , 2002 .
[18] F. Gonzalez,et al. Human cytochromes P450: problems and prospects. , 1992, Trends in pharmacological sciences.
[19] Andreas Zell,et al. Locating Biologically Active Compounds in Medium-Sized Heterogeneous Datasets by Topological Autocorrelation Vectors: Dopamine and Benzodiazepine Agonists , 1996, J. Chem. Inf. Comput. Sci..
[20] F. Darvas,et al. Diversity Measures for Enhancing ADME Admissibility of Combinatorial Libraries. , 2000 .
[21] Ferenc Darvas,et al. Metabolexpert: An Expert System for Predicting Metabolism of Substances , 1987 .
[22] K. Korzekwa,et al. An assessment of the reaction energetics for cytochrome P450-mediated reactions. , 2001, Archives of biochemistry and biophysics.
[23] C. Ioannides. Cytochromes P450 Metabolic and Toxicological Aspects , 1996 .
[24] W. Jaeger,et al. Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.
[25] R. Cattell. The Scree Test For The Number Of Factors. , 1966, Multivariate behavioral research.
[26] K. Kawajiri,et al. Genetic Polymorphisms in the 5 '-Flanking Region Change Transcriptional Regulation of the Human Cytochrome P 45011 E 1 Gene ' , 2008 .
[27] H. Kubinyi,et al. A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.
[28] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[29] A. D. Rodrigues,et al. Use of in vitro human metabolism studies in drug development. An industrial perspective. , 1994, Biochemical pharmacology.
[30] Bernd Beck,et al. Descriptors, physical properties, and drug-likeness. , 2002, Journal of medicinal chemistry.
[31] P. Erhardt,et al. Microsomal O-demethylation, N-demethylation and aromatic hydroxylation in the presence of bisulfite and dithiothreitol. , 1975, Research communications in chemical pathology and pharmacology.
[32] Johann Gasteiger,et al. The comparison of geometric and electronic properties of molecular surfaces by neural networks: Application to the analysis of corticosteroid-binding globulin activity of steroids , 1996, J. Comput. Aided Mol. Des..
[33] F. Gonzalez,et al. The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.
[34] A. Alex,et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[35] Gilles Klopman,et al. META. 1. A Program for the Evaluation of Metabolic Transformation of Chemicals , 1994, J. Chem. Inf. Comput. Sci..
[36] Ajay,et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.
[37] L. Guttman. Some necessary conditions for common-factor analysis , 1954 .
[38] O. Stiffelman,et al. Computer modeling of 3D structures of cytochrome P450s. , 1996, Biochimie.
[39] Ajay,et al. Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.